

## MEDICINES NOTIFICATION

### CLASS 4 MEDICINES DEFECT INFORMATION

Caution in Use

Distribute to Pharmacy / Wholesaler Level

Dear Healthcare Professional


**Napp Pharmaceuticals Limited**

OxyContin 20 mg prolonged release tablets			PL 16950/0098
Batch No	Expiry Date	Pack Size	First Distributed
250630	08 2024	56's	29/10/2021
250869	10 2024	56's	14/02/2022

**Active Pharmaceutical Ingredient:** Oxycodone Hydrochloride

#### Brief description of the problem

Napp Pharmaceuticals Limited have identified an error relating to the Braille printed on the cartons. The Braille message on the Oxycontin 20mg prolonged release tablets incorrectly states strength as 15mg.

Product	Issue	Correct Braille
Oxycontin 20mg prolonged release tablets, PL 16950/0098	Braille message incorrectly states strength as 15mg rather than 20mg.	The <b>correct</b> Braille message should read: 

#### Advice for healthcare professionals

The impacted products are within specification and there is no issue with product quality. Therefore, the affected batches are not being recalled.

Healthcare professionals should confirm when dispensing this product if this medicine is being collected on behalf of somebody else or if the patient will solely rely on Braille, and if needed explain the error in the Braille. The risk of an overdose remains low and any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).



**Advice for patients**

Two batches of Oxycontin 20 mg prolonged release tablets have an incorrect strength printed in Braille on the product pack. The pack contains 20 mg tablets as prescribed and the medicine itself is not affected. Patients are reminded to take the tablets as per the instructions from your prescriber and those found on the dispensing label. OxyContin prolonged release tablets must be swallowed whole and not broken, chewed or crushed or split.

**Further Information**

For medical information and stock control queries please contact: Napp Pharmaceuticals – Tel. 01223 424444, email [medicalinformationuk@napp.co.uk](mailto:medicalinformationuk@napp.co.uk) or [supplies.uk@napp.co.uk](mailto:supplies.uk@napp.co.uk)

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice